March 26-28, 2019

Boston, USA

Day One

Day Two

Registration & Coffee

Chair’s Opening Remarks

Addressing Knowledge Gap in Immune Tolerance Induction by Connecting the Dots Between Transplantation, Allergies & Autoimmune Diseases

Antigen-Specific T Cell Profiles as Therapeutic Targets in Allergy and Autoimmune Disease


  • High-dimensional phenotyping identifies distinct antigen-specific T cell profiles using peripheral blood from patients with allergy and autoimmune diseas
  • Deletion, deviation, anergy, and exhaustion are potential tolerogenic outcomes of therapy
  • Tracking antigen-specific T cells during therapy may be a surrogate for clinical response

Antigen-Specific Immunotherapy for Treatment of Autoimmune Diseases

  • David Wraith Institute Director of Immunology & Immunotherapy and Professor of Immunology , University of Birmingham


  • A review of different approaches for induction of antigen-specific immunotherapy
  • A report on recent clinical trials of the approach for immunotherapy of autoimmune diseases and
  • A discussion on the potential for combination approaches to promote antigenspecific immunotherapy

Antigen Specific Approaches to Food Allergy & Immunogenicity

  • Michael Boyne VP of Product Development & Analytics , Cour Pharmaceuticals


  • Inducing tolerance without immune suppression by harnessing nanoparticle technology
  • Proof of principle data for Peanut Allergy
  • Proof of principle data for Recombinant Proteins

Speed Networking & Morning Refreshments

Protection from Childhood Allergies & Inflammatory Bowel Disease

  • Erika von Mutius Professor of Pediatric Allergology , Dr. von Hauner Children’s Hospital


  • Prevention of allergic and autoimmune diseases in environment rich microbial exposure
  • Potential mechanisms of preventive approach
  • Translational aspects and considerations

Anti-Drug Antibody Responses: Past, Present & Future

  • Jack Ragheb Senior Medical Fellow for Immunology- Global Patient Safety , Eli Lilly


  • Review the history of ADA responses
  • Review the present state of ADA responses
  • Discuss the future state of ADA responses

Antigen-Specific Tolerance for Transplantation

  • Xunrong Luo Director-Translational Research , Duke Transplant Center, Duke University


  • A top-down approach can be used to overcome the complexity of alloantigens for transplantation tolerance
  • Multiple parallel mechanisms involving both innate and adaptive immune cells are implicated for transplantation tolerance
  • B cells play a critical role in tolerance resistance in pre-sensitized hosts

Networking Lunch

Identification & Validation of Novel Targets & Mechanism of Actions for Antigen-Specific Immune Tolerance Induction Antoon Van

Targeted Antigen Delivery to the Liver via Synthetic Glycosylation Induces Robust Antigen-Specific Tolerance


  • Active targeting domains deliver antigen to tolerogenic pathways in the liver, and induce robust antigen-specific tolerance in both mouse and non-human primate models of immunity
  • Our technologies are translational, in that the mechanisms induced are consistent with unmet clinical needs, and our molecules are developable
  • Discuss potential approaches to de-risk MoA’s in higher-order species, and consider their value

Antigen-Specific Tolerance Induction in Rheumatoid Arthritis

  • Ranjeny Thomas Professor of Rheumatology at University of Queensland; Director , Dendright


  • What are the opportunities and challenges of antigen-specific tolerance induction in a systemic inflammatory autoimmune disease?
  • How does the autoimmune induction phase differ from the inflammatory effector phase in rheumatoid arthritis and what are the implications for therapeutic tolerising strategies?
  • What type of immunomonitoring could contribute to evaluation of the outcome of tolerising strategies in rheumatoid arthritis?

Target Identification in Immune-Mediated Disorders Including Autoimmune Diseases, Allergies, Anti-Drug Responses & Tumor Immunology

  • Roland Martin Head- Department of Neuroimmunology & Multiple Sclerosis Research Neurology Clinic , University Hospital Zurich, University Zurich


• Unbiased and systematic identification of target antigens for T cells using combinatorial chemistry and bioinformatics
• Identification of disease-relevant T cells in autoimmune diseases
• How does the autoimmune T cell response relate to recognition of foreign antigens as triggers?

Afternoon Refreshments & Poster Session

Advancing Pre-Clinical Development of Novel Antigen-Specific Immune Tolerance Therapies

TOL2: An Antigen Specific Tolerogenic Therapy for the Treatment of Myasthenia Gravis


  • TOL2 treatment modalities
  • Tolerance induction and maintenance using TOL2
  • Preclinical development of TOL2

Engineering Red Blood Cells for Immune Tolerance Using Cell Squeeze® Technology

  • Finola Moore Associate Director of Immune Tolerance , SQZ Biotechnologies


  • The SQZ process efficiently delivers antigen into red blood cells (RBCs) and primes cells for rapid clearance in the liver and spleen
  • SQZ’d RBCs reduce CD4+ and CD8+ T cell responses against model antigens and human autoantigens
  • SQZ’d RBCs delay or prevent onset of T1D in adoptive transfer model

Panel Discussion: How to Identify & Prioritize the Route to Success for Antigen-Specific Immune Tolerance Induction Strategies?


  • What does it take to achieve a robust proof-of-concept for antigen-specific immune tolerance induction strategies in complex auto-immune mediated diseases?
  • Delivering on the hype and investment thus far – how to translate promising science and clear opportunity into safe and effective antigen-specific tolerance inducing therapeutics?
  • The most promising route to funding: how to secure funding, through cross-industry collaborations, to fuel early clinical trial studies and beyond?

Chair’s Closing Remarks & End of Day One